Holistic Way launches 4 new health supplements in Malaysia
Addressing Modern Health Challenges
In today's demanding lifestyle, maintaining optimal health has become increasingly challenging. Recognizing this growing need, Holistic Way—founded in 2007 by Ricky Ong under JR Life Sciences—has developed these targeted solutions to support Malaysians in their daily wellness journey.
'Health is not just physical, it's the quality and depth of life,' reflects the brand's core philosophy of 'Health In Harmony,' which has guided their commitment to scientifically validated, premium supplements for nearly two decades.
Four Game-Changing Formulas
1. Super ActiveFlex with UC-II® - Revolutionary Joint Support
This advanced joint formula features clinically proven UC-II® undenatured Type II collagen, demonstrated to be more effective than traditional glucosamine and chondroitin. Perfect for both aging adults experiencing knee stiffness and younger individuals seeking proactive joint care.
2. BiO-NMN Long-evity - Cellular Energy Powerhouse
Featuring NMN (Nicotinamide Mononucleotide), often called the 'key to youth,' this formula targets cellular health and energy regeneration. Ideal for combating fatigue, mental fog, and supporting healthy aging at the cellular level.
3. Super Barley Wheat Greens - Daily Nutritional Insurance
Packed with 14 superfoods including barley grass, wheatgrass, carrot, and spinach, this fiber-rich blend addresses the common Malaysian challenge of insufficient fruit and vegetable intake, supporting digestion and gut health.
4. Super Greens D-Tox Enzymes - Natural Cleansing Solution
A sophisticated blend of super greens, digestive enzymes, and natural ingredients like senna extract, designed for gentle yet effective detoxification and digestive wellness.
Exclusive Guardian Partnership
The prestigious launch event featured key industry leaders including Ricky Ong (Managing Director, JR Life Sciences), Jeffrey Kee (Director, Holistic Way Sdn Bhd), Sheryn (Head of Commercial Healthcare, Guardian), and Lee CH (Senior General Manager of Marketing, Pavilion KL).
All four products are now exclusively available at Guardian outlets nationwide and through Holistic Way's official Shopee and Lazada flagship stores.
A Commitment to Malaysian Wellness
With over a decade of expertise in premium health supplements, Holistic Way's expansion into Malaysia represents a significant milestone in making evidence-based wellness solutions more accessible to Malaysian families.
The brand's focus on plant-based formulations, rigorous scientific support, and trusted safety standards positions these new products as smart choices for health-conscious Malaysians who prioritize quality of life.
For more information, visit holisticway.com.my
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
an hour ago
- The Sun
Guardian Malaysia launches 'Skin So Super' campaign
In celebration of World Skin Health Day this July, Guardian Malaysia — the country's No. 1 Health & Beauty Retailer* — is going all out to honour the vital role of skin in overall health and wellbeing with a month-long nationwide campaign titled 'Skin So Super', running from 2 to 29 July. The highlight of this initiative is the 1st Skin So Super Atrium Experience, happening at Sunway Pyramid on 26 and 27 July. 'This campaign is our reimagination of how our shoppers should care for their skin and overall wellbeing,' said Anna Ng, Marketing Director of Guardian Malaysia. 'When our skin is healthy, wellbeing follows — and vice versa. When we are well within, our skin glows without.' Guided by this year's World Skin Health Day theme, 'No Health Without Skin Health', Guardian's campaign promotes both skin function and appearance — because healthy skin is more than just skin-deep. A Month of Skincare & Wellness The Skin So Super campaign features special promotions across Guardian stores nationwide and online. Key skincare categories include: - Derma/Sensitive - Brightening & Suncare - Youth Boosting (Anti-Aging) - Acne Solutions Supporting brands in health and inner wellness will also be featured — helping Malaysians achieve radiant, healthy skin from the inside out. Customers can consult Guardian pharmacists and brand beauty advisors at any store or during the Atrium Experience for personalised advice on skincare concerns or to optimise their current routine. 'We have the experts and expertise to advise you on all things skin,' Anna added. An interactive Skin So Super campaign page is also live at: Here, users can explore skincare products, take guided quizzes, and learn from dermatologist tips, videos, and the SkinLab guide to healthier skin. What to Expect at the Skin So Super Atrium Experience - Sunway Pyramid - 26 & 27 July 2025 - 10am–10pm (Starts at 12:30pm on 26 July) Get ready for a weekend of immersive skincare and wellness experiences featuring: - 100 participating brands - Brand booths & live demos - Workshops & masterclasses - Personalised skin consultations - Wellness sharing sessions - Interactive Beauty Zones (Skin Lab, Acne, Healthy Aging, Sun Smart) - Wellbeing Zones (Inner Wellness, Power Up) Exclusive Offers - Special discounts - Purchase-with-Purchase (PWP) deals - Gift-with-Purchase (GWP) goodies - Exclusive workshops for MyGuardian Rewards members Workshop tickets available via the MyGuardian Rewards app or online:
Daily Express
an hour ago
- Daily Express
RM40 biliion allocation to implement healthcare reforms
Published on: Friday, August 01, 2025 Published on: Fri, Aug 01, 2025 Text Size: Queen Elizabeth Hospital 2. Kuala Lumpur: The Federal Government has allocated RM40 billion under the 13th Malaysia Plan (13MP) 2026 to 2030 to implement wide-ranging reforms in the healthcare sector, Prime Minister Datuk Seri Anwar Ibrahim announced Thursday. He said the healthcare reform agenda is a vital government initiative to ensure sustainable health financing while expanding access to quality and affordable healthcare services for all Malaysians, which is also aimed at increasing service options for patients without compromising on cost or quality. To strengthen medical supply security, Anwar said domestic pharmaceutical manufacturing would be encouraged, while the use of generic medicines in both the public and private sectors would be significantly increased. 'Pro-health taxes will be expanded from sugar to products such as tobacco, vape and alcohol, not just for revenue but to encourage behavioural change and curb the increase in non-communicable diseases (NCDs) which is increasingly worrying,' he said. Another key objective of the reform, Anwar said, is to reduce the out-of-pocket healthcare expenses borne by citizens. Under the 13MP, more hospitals and clinics - including those in dilapidated condition - will be built or upgraded to improve healthcare delivery nationwide. Major projects slated for development include Hospital Tuanku Ja'afar 2 in Seremban, Hospital Sultanah Aminah 2 in Johor Bahru, the Northern Region Cancer Centre in Sungai Petani, the Sabah Heart Centre at Hospital Queen Elizabeth II in Kota Kinabalu, and the Sarawak Cancer Centre. To address long-standing workforce challenges, the government will also introduce a national framework for health sector talent development. 'This includes initiatives covering pre-service training, licensing, recruitment, placement, and career development, all aimed at retaining and nurturing skilled professionals in the healthcare system,' Anwar said. Anwar also announced that health record management will be strengthened as part of the core strategy for digitising Malaysia's healthcare infrastructure, which will enhance interoperability between healthcare facilities and enable seamless patient data access. The digitisation push will also lay the groundwork for high-impact health analytics powered by artificial intelligence (AI), further enhancing the quality and responsiveness of healthcare services in Malaysia, he added. * Follow us on our official WhatsApp channel and Telegram for breaking news alerts and key updates! * Do you have access to the Daily Express e-paper and online exclusive news? Check out subscription plans available. Stay up-to-date by following Daily Express's Telegram channel. Daily Express Malaysia
Malaysian Reserve
5 hours ago
- Malaysian Reserve
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) witho
FDA approval is based on phase 3 trial data (explorer8), which established the safety and efficacy of Alhemo® (concizumab-mtci) injection in people 12 years and older with hemophilia A or B (HA/HB) without inhibitors1 Results showed a 79% reduction in annualized bleeding rate (ABR) in patients with HB without inhibitors and an 86% reduction in patients with HA without inhibitors, respectively, using Alhemo® prophylaxis compared to no prophylaxis2 Alhemo® was the first subcutaneous injectable pen of its kind for patients living with HA and HB with inhibitors and is now approved for those living without inhibitors1 PLAINSBORO, N.J., July 31, 2025 /PRNewswire/ — Novo Nordisk announced today that the US Food and Drug Administration (FDA) approved Alhemo® (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors, expanding on the December 2024 approval for HA/HB with inhibitors.1,2,3 Currently, many treatments for HA/HB without inhibitors are administered via intravenous infusions.2 With this approval, Alhemo® now offers a subcutaneous injection treatment option for this population.1 'The FDA approval of an expanded indication for Alhemo® marks a meaningful step forward for people with hemophilia A or B without inhibitors who are looking for a new prophylaxis treatment option,' said Anna Windle, PhD, Senior Vice President, Clinical Development, Medical & Regulatory Affairs, Novo Nordisk. 'By building on the initial indication for Alhemo® for those with hemophilia with inhibitors—an especially significant development in hemophilia B where challenges still exist despite advanced treatment options—Novo Nordisk continues its 35+ year legacy in rare bleeding disorders to continue to help address the unmet needs of this community.' Alhemo® is designed to block a protein called tissue factor pathway inhibitor (TFPI), which stops blood from clotting. By inhibiting TFPI, Alhemo® improves the production of thrombin, which helps to clot the blood and prevent bleeding, when clotting factors VIII and IX are missing or deficient regardless of inhibitor status.4,5 'For people living with hemophilia, it is important to continually monitor and discuss bleed control with their healthcare professional,' said Allison P. Wheeler, MD, Scientific Director, Washington Center for Bleeding Disorders, Seattle, WA. 'With today's approval of Alhemo® for hemophilia A or B without inhibitors, more people living with these rare blood disorders now have a daily prophylaxis option that may help decrease their bleeding rates.' The primary objective of the pivotal phase 3 explorer8 trial was to compare the number of treated spontaneous and traumatic bleeding episodes, as measured by the ABR, in patients aged 12 years and older with HA/HB without inhibitors, receiving Alhemo® prophylaxis versus no prophylaxis (on demand Factor VIII/Factor IX treatment).2 The study showed a statistically significant reduction in ABR of 79% for HB patients (ABR ratio: 0.21; 95% CI: 0.10–0.45; p<0.0001) and 86% for HA patients (ABR ratio: 0.14; 95% CI: 0.07–0.29; p<0.0001). Additionally, notable reductions in the average and median ABRs further reinforced the efficacy of Alhemo® prophylaxis in reducing bleeds across both patient groups, with an average ABR of 3.1 (1.9-5.0) and a median ABR of 1.6 (0.0-4.8) for HB patients, compared to 14.8 (8.1-26.9) and 14.9 (3.3-22.1), respectively, and an average ABR of 2.7 (1.6-4.6) and median ABR of 2.9 (0.0-5.2) for HA patients, compared to 19.3 (11.3-33.0) and 19.6 (17.3-30.4), respectively. In the study, the most common adverse reactions reported in ≥5% of patients randomized to receive Alhemo® were injection site reactions (7%) and headache (7%).1 Alhemo® is provided in prefilled, premixed pens for subcutaneous injection (60 mg/1.5 mL, 150 mg/1.5 mL, or 300 mg/3 mL) via thin 32 gauge, 4 mm needles, which are provided separately, offering an additional treatment choice for patients with hemophilia with inhibitors – and now without inhibitors – to further customize their care. About the explorer8 studyExplorer8 is a phase 3 clinical trial that evaluated the efficacy and safety of Alhemo® for adults and pediatric patients 12 years of age and older living with hemophilia A or B (HA/HB) without inhibitors.2 In explorer8, among the 156 males with HA/HB included in the trial, 63 were randomly assigned in a 1:2 ratio to receive no prophylaxis (arm 1, n=21), or Alhemo® prophylaxis (arm 2, n=42).2,6 The median duration of treatment was 24.1 weeks in arm 1 (no prophylaxis) and 32.1 weeks in arm 2 (Alhemo® prophylaxis).The initial loading dose of Alhemo® was 1 mg per kilogram of body weight, followed by 0.2 mg per kilogram daily, and potentially individualized on the basis of concizumab-mtci plasma concentration as measured at week 4.1,2 Efficacy was evaluated separately in HA patients without inhibitors and in HB patients without inhibitors when all patients in arms 1 and 2 had completed the main part of the trial (at least 24 or at least 32 weeks, respectively), based on the number of treated bleeding episodes comparing Alhemo® prophylaxis and no prophylaxis.1 About Alhemo® (concizumab-mtci) Alhemo® is a tissue factor pathway inhibitor (TFPI) antagonist. By inhibiting the TFPI, Alhemo® enhances factor Xa (FXa) production during the initiation phase of coagulation, leading to improved thrombin generation and clot formation in patients with hemophilia A or B (HA/HB) with or without inhibitors. The effect of Alhemo® is not influenced by the presence of inhibitory antibodies to FVIII or FIX and Alhemo® does not induce or enhance the development of direct inhibitors to FVIII or FIX. Alhemo® is approved as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with HA/HB with or without inhibitors in the US.1 What is Alhemo®?Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A or B with or without factor VIII or IX inhibitors. It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age Important Safety Information What is the most important information I should know about Alhemo®? It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding Your HCP may prescribe factor VIII, factor IX, or bypassing agents during treatment with Alhemo®. Carefully follow your HCP's instructions regarding when to use on-demand factor VIII, factor IX, or bypassing agents and the recommended dose and schedule for breakthrough bleeds Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®. Before using Alhemo®, tell your HCP about all of your medical conditions, including if you: Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery Are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk Your HCP may do a pregnancy test before you start treatment with Alhemo® Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment Your HCP may do a pregnancy test before you start treatment with Alhemo® Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements. What are the possible side effects of Alhemo®?Alhemo® may cause serious side effects, including: Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat The most common side effects of Alhemo® include: bruising, redness, bleeding, itching, rash or lump at the injection site, headache, and hives. These are not all the possible side effects of Alhemo®. Call your doctor for medical advice about side effects. Please click HERE for Alhemo® Prescribing Information and Medication Guide About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.7 It is estimated to affect approximately ~800,000 people worldwide.8 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing. Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX (FIX).7 Hemophilia is often treated by replacing the missing clotting factor via intravenous infusions, also known as replacement therapy.8 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. References Alhemo® (concizumab-mtci) injection, for subcutaneous use [package insert]. Plainsboro, NJ: Novo Nordisk Inc. Chowdary P., et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Hematology. 2024;11:e891-904. Novo Nordisk. FDA approves drug to prevent or reduce the frequency of bleeding episodes for patients with hemophilia A with inhibitors or hemophilia B with inhibitors. Accessed May 2025. Available at Shapiro AD. Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv. 2021;5(1):279. Matsushita T, Shapiro A, Abraham A, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023; 389(9): 783-794. Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors (explorer8). Accessed May 2025. Available at MedlinePlus. Hemophilia. Accessed May 2025. Available at World Federation of Hemophilia. Annual Global Survey 2023. Accessed July 2025. Further information Liz Skrbkova (US)+1 609 917 0632 (Mobile)USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Alhemo® is a registered trademark of Novo Nordisk Health Care AG. Novo Nordisk is a registered trademark of Novo Nordisk A/S.© 2025 Novo Nordisk All rights reserved. US25AHM00187 July 2025
